Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Position Lifted by Privium Fund Management B.V.

Privium Fund Management B.V. grew its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 12.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 134,900 shares of the company’s stock after acquiring an additional 14,900 shares during the period. Privium Fund Management B.V. owned about 0.07% of Taysha Gene Therapies worth $233,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. lifted its holdings in Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock worth $820,000 after buying an additional 11,390 shares during the last quarter. Cibc World Markets Corp acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at approximately $28,000. E Fund Management Co. Ltd. bought a new position in Taysha Gene Therapies during the fourth quarter worth $31,000. Quantum Private Wealth LLC boosted its holdings in Taysha Gene Therapies by 3.6% in the fourth quarter. Quantum Private Wealth LLC now owns 794,976 shares of the company’s stock worth $1,375,000 after purchasing an additional 27,360 shares during the period. Finally, Commonwealth Equity Services LLC boosted its holdings in Taysha Gene Therapies by 110.4% in the fourth quarter. Commonwealth Equity Services LLC now owns 59,069 shares of the company’s stock worth $102,000 after purchasing an additional 31,000 shares during the period. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

NASDAQ TSHA opened at $1.74 on Wednesday. The company has a 50-day moving average price of $1.64 and a two-hundred day moving average price of $1.93. Taysha Gene Therapies, Inc. has a 52 week low of $1.19 and a 52 week high of $4.32. The stock has a market cap of $356.70 million, a price-to-earnings ratio of 2.76 and a beta of 0.91. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The business had revenue of $2.02 million during the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. Analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on TSHA shares. Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Thursday, February 27th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.